06:59 AM EDT, 07/30/2024 (MT Newswires) -- Merck ( MRK ) reported Q2 non-GAAP earnings Tuesday of $2.28 per diluted share, swinging from an adjusted loss of $2.06 per share a year earlier.

Analysts polled by Capital IQ expected normalized EPS of $2.14.

Sales for the quarter ended June 30 were $16.11 billion, compared with $15.04 billion a year earlier.

Analysts polled by Capital IQ expected $15.84 billion.

For 2024, the company said it now expects full-year non-GAAP EPS of $7.94 to $8.04, from the previous range of $8.53 to $8.65. Analysts polled by Capital IQ expect $8.45.

Sales for the year are projected to be $63.4 billion to $64.4 billion, compared with the previous forecast of $63.1 billion to $64.3 billion. Analysts polled by Capital IQ expect $64.25 billion.

Price: 124.27, Change: -3.51, Percent Change: -2.75